An open-label study investigating the efficacy and safety of 12 - 96 weeks of telmisartan treatment in patients with hypertension

C. Ingino, C. Farsang, A. Laucevicius, M. Bergovec

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

This open-label, multicentre, multinational trial evaluated the efficacy and safety of telmisartan used alone or as add-on therapy in 2121 adults with mild-to-moderate essential hypertension. Patients received telmisartan 40-80 mg once daily for 12 weeks and could participate in the study for up to 96 weeks, or until a marketed supply of telmisartan became available. Mean change from baseline in mean seated trough diastolic blood pressure (DBP) after 12 weeks' treatment, the primary endpoint, was -11.8 mmHg in the intent-to-treat population. The corresponding mean change in mean seated trough systolic blood pressure (SBP) was -20.2 mmHg. Both changes were statistically significant. Mean DBP and SBP reductions were apparent from week 4 and maintained throughout the treatment period. Telmisartan was well tolerated; the most common adverse events were headache (6%) and dizziness (3%), and 10% of adverse events were considered drug-related. In conclusion, telmisartan is an effective and well-tolerated drug when used as monotherapy or add-on treatment in this broad population of patients.

Original languageEnglish
Pages (from-to)561-574
Number of pages14
JournalJournal of International Medical Research
Volume31
Issue number6
DOIs
Publication statusPublished - Jan 1 2003

Keywords

  • Angiotensin II receptor blocker
  • Blood pressure control
  • Hypertension
  • Telmisartan

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'An open-label study investigating the efficacy and safety of 12 - 96 weeks of telmisartan treatment in patients with hypertension'. Together they form a unique fingerprint.

  • Cite this